Key Findings
The Asia-Pacific cancer biomarkers market is expected to rise with a CAGR of 13.23% for the years 2019-2027. Development in the healthcare facility in the region and growing government efforts to increase awareness are the major driving force for the market in the Asia Pacific region.

Market Insights
The economies studied in the APAC region include China, Japan, India, Australia, South Korea and Rest of APAC. India and China are the prime countries contributing highest in the APAC cancer biomarker market. Moreover, the adoption of western lifestyles in developing countries, prevailing high population and the growing cancer research in the Asian countries are also accelerating the growth of the market. However, the low estimated rate for successful clinical trials and the various technical issues related to cancer biomarkers is expected to challenge the market growth over the forecasting period.

Competitive Insights
Some of the established companies in this market are Astellas Pharma Inc., Celgene Corporation, Diadexus Inc. (Acquired By Diazyme Laboratories), Becton Dickinson and Company, Abbott Laboratories, Bristol-Myers Squibb, Sanofi, Clarient, Inc. (Acquired By Neogenomics Laboratories), Aureon Biosciences, Inc., Illumina, Inc., Roche Diagnostics Ltd., Agilent Technologies, Inc., Qiagen N.V., Agendia N.V. and Beckman Coulter.